BRIDGEWATER, NJ, April 7, 2022 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company whose mission is to transform the lives of patients with serious and rare diseases, today announced the awarding of incentive awards to 20 new employees. In accordance with NASDAQ listing rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee and made as a material incentive for each employee to enter the company.
As part of their entry into service, employees received options on April 1, 2022 purchase a total of 107,680 ordinary shares of Insmed at an exercise price of $24.47 per share, the closing price on the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to vesting. options vest every six months. thereafter until the fourth anniversary of the relevant grant date, subject to the relevant employee’s continued employment with Insmed on the applicable vesting date.
Insmed Incorporated is a global biopharmaceutical company whose mission is to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is a first disease therapy approved in United States, Europeand Japan to treat chronic and debilitating lung disease. The Company is also developing a strong portfolio of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare lung disorders. Insmed is headquartered in Bridgewater, New Jerseywith a footprint through Europe and in Japan. For more information, visit www.insmed.com.
Associate Director, Investor Relations
Executive Director, Corporate Communications